Bausch Health Cos Current Ratio 2012-2025 | BHC
Bausch Health Cos current ratio from 2012 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Bausch Health Cos Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-12-31 | $6.16B | $4.18B | 1.47 |
| 2025-09-30 | $6.25B | $4.79B | 1.30 |
| 2025-06-30 | $6.51B | $4.98B | 1.31 |
| 2025-03-31 | $5.73B | $4.26B | 1.35 |
| 2024-12-31 | $5.77B | $6.75B | 0.86 |
| 2024-09-30 | $5.35B | $4.51B | 1.19 |
| 2024-06-30 | $5.21B | $4.37B | 1.19 |
| 2024-03-31 | $5.40B | $4.41B | 1.23 |
| 2023-12-31 | $5.60B | $4.30B | 1.30 |
| 2023-09-30 | $5.05B | $4.22B | 1.20 |
| 2023-06-30 | $4.46B | $3.97B | 1.13 |
| 2023-03-31 | $4.24B | $3.92B | 1.08 |
| 2022-12-31 | $4.25B | $3.94B | 1.08 |
| 2022-09-30 | $4.01B | $3.83B | 1.05 |
| 2022-06-30 | $5.42B | $5.00B | 1.08 |
| 2022-03-31 | $5.84B | $4.77B | 1.22 |
| 2021-12-31 | $5.61B | $5.20B | 1.08 |
| 2021-09-30 | $5.32B | $5.44B | 0.98 |
| 2021-06-30 | $5.45B | $5.52B | 0.99 |
| 2021-03-31 | $5.39B | $4.90B | 1.10 |
| 2020-12-31 | $5.34B | $4.91B | 1.09 |
| 2020-09-30 | $5.67B | $4.73B | 1.20 |
| 2020-06-30 | $5.28B | $4.72B | 1.12 |
| 2020-03-31 | $5.50B | $4.89B | 1.13 |
| 2019-12-31 | $6.97B | $6.25B | 1.12 |
| 2019-09-30 | $4.31B | $3.74B | 1.15 |
| 2019-06-30 | $4.47B | $3.71B | 1.21 |
| 2019-03-31 | $4.28B | $3.94B | 1.09 |
| 2018-12-31 | $4.21B | $3.84B | 1.10 |
| 2018-09-30 | $4.74B | $4.16B | 1.14 |
| 2018-06-30 | $4.64B | $4.07B | 1.14 |
| 2018-03-31 | $4.72B | $3.99B | 1.18 |
| 2017-12-31 | $4.75B | $4.27B | 1.11 |
| 2017-09-30 | $5.94B | $4.73B | 1.26 |
| 2017-06-30 | $5.99B | $4.47B | 1.34 |
| 2017-03-31 | $5.33B | $4.25B | 1.26 |
| 2016-12-31 | $5.08B | $3.61B | 1.41 |
| 2016-09-30 | $5.67B | $3.90B | 1.46 |
| 2016-06-30 | $5.82B | $4.23B | 1.38 |
| 2016-03-31 | $6.23B | $4.60B | 1.36 |
| 2015-12-31 | $5.51B | $5.31B | 1.04 |
| 2015-09-30 | $7.00B | $4.65B | 1.50 |
| 2015-06-30 | $6.35B | $4.29B | 1.48 |
| 2015-03-31 | $16.19B | $3.10B | 5.23 |
| 2014-12-31 | $4.13B | $2.71B | 1.53 |
| 2014-09-30 | $4.41B | $3.14B | 1.40 |
| 2014-06-30 | $5.16B | $2.50B | 2.07 |
| 2014-03-31 | $3.95B | $2.56B | 1.54 |
| 2013-12-31 | $3.89B | $2.51B | 1.55 |
| 2013-09-30 | $3.85B | $2.85B | 1.35 |
| 2013-06-30 | $4.53B | $1.76B | 2.57 |
| 2013-03-31 | $2.37B | $1.65B | 1.44 |
| 2012-12-31 | $2.78B | $1.82B | 1.52 |
| 2012-09-30 | $1.71B | $1.16B | 1.48 |
| 2012-06-30 | $1.63B | $1.05B | 1.55 |
| 2012-03-31 | $1.53B | $0.96B | 1.60 |
| 2011-12-31 | $1.36B | $0.92B | 1.47 |
| 2011-09-30 | $1.10B | $0.86B | 1.27 |
| 2011-06-30 | $1.05B | $0.76B | 1.37 |
| 2011-03-31 | $1.28B | $0.66B | 1.93 |
| 2010-12-31 | $1.02B | $0.69B | 1.47 |
| 2010-09-30 | $1.30B | $0.85B | 1.54 |
| 2010-06-30 | $0.41B | $0.23B | 1.77 |
| 2010-03-31 | $0.34B | $0.21B | 1.63 |
| 2009-12-31 | $0.34B | $0.25B | 1.38 |
| 2009-09-30 | $0.25B | $0.22B | 1.14 |
| 2009-06-30 | $0.25B | $0.22B | 1.13 |
| 2009-03-31 | $0.47B | $0.23B | 2.03 |
| 2008-12-31 | $0.49B | $0.27B | 1.84 |
| 2008-09-30 | $0.42B | $0.19B | 2.21 |
| 2008-06-30 | $0.66B | $0.35B | 1.89 |
| 2008-03-31 | $0.74B | $0.39B | 1.88 |
| 2007-12-31 | $0.71B | $0.37B | 1.92 |
| 2007-09-30 | $0.62B | $0.23B | 2.69 |
| 2007-06-30 | $0.67B | $0.28B | 2.44 |
| 2007-03-31 | $1.08B | $0.74B | 1.46 |
| 2006-12-31 | $1.06B | $0.41B | 2.58 |
| 2006-09-30 | $0.93B | $0.27B | 3.39 |
| 2006-06-30 | $0.79B | $0.26B | 3.09 |
| 2006-03-31 | $0.72B | $0.26B | 2.74 |
| 2005-12-31 | $0.69B | $0.27B | 2.50 |
| 2005-09-30 | $0.56B | $0.21B | 2.70 |
| 2005-06-30 | $0.46B | $0.22B | 2.05 |
| 2005-03-31 | $0.33B | $0.19B | 1.71 |
| 2004-12-31 | $0.32B | $0.19B | 1.65 |
| 2004-09-30 | $0.32B | $0.25B | 1.26 |
| 2004-06-30 | $0.31B | $0.25B | 1.26 |
| 2004-03-31 | $0.32B | $0.23B | 1.41 |
| 2003-12-31 | $0.41B | $0.26B | 1.57 |
| 2003-09-30 | $0.40B | $0.34B | 1.18 |
| 2003-06-30 | $0.41B | $0.32B | 1.28 |
| 2003-03-31 | $0.30B | $0.34B | 0.88 |
| 2002-12-31 | $0.32B | $0.35B | 0.93 |
| 2002-09-30 | $0.34B | $0.22B | 1.54 |
| 2002-06-30 | $0.24B | $0.22B | 1.10 |
| 2002-03-31 | $0.55B | $0.17B | 3.29 |
| 2001-12-31 | $0.58B | $0.15B | 3.88 |
| 2001-09-30 | $0.19B | $0.21B | 0.91 |
| 2001-06-30 | $0.20B | $0.22B | 0.91 |
| 2001-03-31 | $0.18B | $0.25B | 0.72 |
| 2000-12-31 | $0.26B | $0.29B | 0.91 |
| 2000-09-30 | $0.51B | $0.07B | 7.65 |
| 2000-06-30 | $0.62B | $0.06B | 9.68 |
| 2000-03-31 | $0.59B | $0.06B | 9.40 |
| 1999-12-31 | $0.34B | $0.07B | 4.58 |
| 1999-09-30 | $0.09B | $0.05B | 2.00 |
| 1999-06-30 | $0.14B | $0.03B | 4.65 |
| 1999-03-31 | $0.14B | $0.03B | 4.57 |
| 1998-12-31 | $0.14B | $0.02B | 6.12 |
| 1998-09-30 | $0.07B | $0.03B | 2.42 |
| 1998-06-30 | $0.07B | $0.02B | 3.68 |
| 1998-03-31 | $0.07B | $0.02B | 3.54 |
| 1997-12-31 | $0.00B | 0.00 | |
| 1997-09-30 | $0.00B | 0.00 | |
| 1997-06-30 | $0.04B | $0.02B | 1.94 |
| 1997-03-31 | $0.03B | $0.02B | 1.79 |
| 1996-12-31 | $0.03B | $0.02B | 1.57 |
| 1996-09-30 | $0.03B | $0.03B | 1.19 |
| 1996-06-30 | $0.04B | $0.04B | 1.08 |
| 1996-03-31 | $0.01B | $0.00B | 6.02 |
| 1995-12-31 | $0.04B | $0.03B | 1.02 |
| 1995-09-30 | $0.00B | 0.00 | |
| 1995-06-30 | $0.00B | 0.00 | |
| 1995-03-31 | $0.00B | 0.00 | |
| 1994-12-31 | $0.01B | $0.01B | 1.07 |
| 1994-09-30 | $0.00B | 0.00 | |
| 1994-06-30 | $0.01B | $0.01B | 0.75 |
| 1994-03-31 | $0.00B | 0.00 | |
| 1993-12-31 | $0.01B | $0.01B | 1.52 |
| 1993-09-30 | $0.01B | $0.01B | 0.57 |
| 1992-12-31 | $0.01B | $0.01B | 0.63 |
| 1991-12-31 | $0.00B | $0.00B | 0.00 |
| 1991-03-31 | $0.00B | $0.00B | 0.00 |
| 1990-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |